TP53 and lip and oral cavity carcinoma: In our previous studies, we have demonstrated that TPL also inhibited cell growth in oral cancer xenograft models.35, 36 Furthermore, a novel compound derived from diterpene triepoxide was demonstrated to reactivate p53 function and significantly decrease tumor progression and volume in vitro, in vivo, and in a PDTX model of human papillomavirus‐positive head and neck squamous cell carcinoma.58 Taken together, these results indicated that TPL might be a potential adjuvant drug for OSCC.